Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

Stopped It was difficult to enroll patients during the pandemic. A new oral drug, Avapritinib, has since been approved for systemic mastocytosis. This medication controls skin manifestations of mastocytosis and is more convenient for patients to use.

Conditions

• Cutaneous Mastocytoses

Interventions

• COMBINATION_PRODUCT: Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.

Sponsor

Joseph Butterfield